Panel Discussions of Practical Considerations of Futility Analysis
*Keaven Anderson, Merck & Company *Susan Ellenberg, University of Pennsylvania *Scott Evans, Harvard *John Lawrence, FDA *Benjamin Trzaskoma, Genentech *Jialu Zhang, FDA Keywords: This session will consist of two 20-minute oral presentations, one from industry and one from the FDA, followed by a 35-minute panel discussion with representations from industry, FDA, academia and DMCs. The focus is to discuss the challenges and needs from different perspectives and seek better ways to collaborate in the future regarding the design, implementation, and trial integrity of interim analyses and futility analyses.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC